By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Entest Biomedical, Inc. 

San Diego  California    U.S.A.
Phone: n/a Fax:


Medical Device

Company News
Entest Biomedical, Inc.'s Zander Therapeutics, Inc. Unit Announces Publication Of Canine Cellular Immunotherapy Patent Application For Treating Cancer In Dogs 2/15/2017 6:43:37 AM
Entest Biomedical, Inc.'s Subsidiary Zander Therapeutics Makes Key Additions To Management Team As The Company Prepares To Move Forward In The $63 Billion Veterinary / Pet Market Niche 2/6/2017 9:06:32 AM
Entest Biomedical, Inc. Chairman David Koos Discusses Zander Therapeutics Subsidiary And Future Plans For The Company Moving Into 2017 12/27/2016 9:52:03 AM
Entest Biomedical, Inc.'s Zander Therapeutics Unit Files Composition Of Matter Patent On NR2F6 Modulating Small Molecules In Canine And Feline Applications 10/20/2016 10:44:46 AM
Entest Biomedical, Inc.'s Zander Therapeutics Unit Files Patent Application On Ex Vivo Activated Autologous Immune Cells 8/11/2015 6:57:22 AM
Entest Biomedical, Inc.'s Zander Therapeutics Unit: Initial Focus Is Small Molecule And Cancer Stem Targeting For Veterinary Oncology 8/4/2015 8:32:45 AM
Entest Biomedical, Inc. In Discussions To Acquire Nanotechnology Delivery System For Cancer Therapy 6/2/2015 10:45:27 AM
Entest Biomedical, Inc. Recruits Salk Institute for Biological Studies Researcher To Lead Cancer Stem Cell Program For Treating Feline Leukemia And Canine Cancer 7/16/2014 10:31:26 AM
Entest Biomedical, Inc.'s ImenVax(TM) Cancer Vaccine Appears to Slow Tumor Growth in Advanced Canine Cancer Cases Without Hazardous Side Effects 9/6/2012 9:42:53 AM
Entest Biomedical, Inc. Sees Entry into $300 Million Veterinary Cancer Care Market Through Veterinary Hospital Acquisitions 9/4/2012 9:34:35 AM